Tumor Lysis Syndrome Following Treatment with 2-Chlorodeoxyadenosine for Refractory Chronic Lymphocytic Leukemia

Eldad J. Dann; Shmuel Gillis; Aaron Polliack; Elimelech Okon; Deborah Rund; Eliezer A. Rachmilewitz

doi:10.1056/NEJM199311183292106

Tumor Lysis Syndrome Following Treatment with 2-Chlorodeoxyadenosine for Refractory Chronic Lymphocytic Leukemia

Eldad J. Dann, Shmuel Gillis, Aaron Polliack, Elimelech Okon, Deborah Rund, Eliezer A. Rachmilewitz

Hadassah University Medical Centre

Research output: Contribution to journal › Article › peer-review

30 Scopus citations

Abstract

The deoxyadenosine analogue 2-chlorodeoxyadenosine is an effective and relatively nontoxic treatment for hairy-cell leukemia¹ and other B-cell neoplasms, including chronic lymphocytic leukemia (CLL)²,³. In a recent study of 90 patients with CLL, including 62 with advanced disease, the overall rate of response was 44 percent, the most severe toxic effect being myelosuppression⁴. Excellent responses were recently reported in four patients who did not respond to fludarabine therapy, with myelosuppression as the only untoward side effect⁵. We report the occurrence of tumor lysis syndrome after the infusion of 2-chlorodeoxyadenosine in a patient with CLL and bulky lymphadenopathy…

Original language	English
Pages (from-to)	1547-1548
Number of pages	2
Journal	New England Journal of Medicine
Volume	329
Issue number	21
DOIs	https://doi.org/10.1056/NEJM199311183292106
State	Published - 18 Nov 1993
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1056/NEJM199311183292106

Cite this

@article{3a0c7a81e60c49f8b0d55c11daf5583e,

title = "Tumor Lysis Syndrome Following Treatment with 2-Chlorodeoxyadenosine for Refractory Chronic Lymphocytic Leukemia",

abstract = "The deoxyadenosine analogue 2-chlorodeoxyadenosine is an effective and relatively nontoxic treatment for hairy-cell leukemia1 and other B-cell neoplasms, including chronic lymphocytic leukemia (CLL)2,3. In a recent study of 90 patients with CLL, including 62 with advanced disease, the overall rate of response was 44 percent, the most severe toxic effect being myelosuppression4. Excellent responses were recently reported in four patients who did not respond to fludarabine therapy, with myelosuppression as the only untoward side effect5. We report the occurrence of tumor lysis syndrome after the infusion of 2-chlorodeoxyadenosine in a patient with CLL and bulky lymphadenopathy…",

author = "Dann, {Eldad J.} and Shmuel Gillis and Aaron Polliack and Elimelech Okon and Deborah Rund and Rachmilewitz, {Eliezer A.}",

year = "1993",

month = nov,

day = "18",

doi = "10.1056/NEJM199311183292106",

language = "אנגלית",

volume = "329",

pages = "1547--1548",

journal = "New England Journal of Medicine",

issn = "0028-4793",

publisher = "Massachussetts Medical Society",

number = "21",

}

TY - JOUR

T1 - Tumor Lysis Syndrome Following Treatment with 2-Chlorodeoxyadenosine for Refractory Chronic Lymphocytic Leukemia

AU - Dann, Eldad J.

AU - Gillis, Shmuel

AU - Polliack, Aaron

AU - Okon, Elimelech

AU - Rund, Deborah

AU - Rachmilewitz, Eliezer A.

PY - 1993/11/18

Y1 - 1993/11/18

N2 - The deoxyadenosine analogue 2-chlorodeoxyadenosine is an effective and relatively nontoxic treatment for hairy-cell leukemia1 and other B-cell neoplasms, including chronic lymphocytic leukemia (CLL)2,3. In a recent study of 90 patients with CLL, including 62 with advanced disease, the overall rate of response was 44 percent, the most severe toxic effect being myelosuppression4. Excellent responses were recently reported in four patients who did not respond to fludarabine therapy, with myelosuppression as the only untoward side effect5. We report the occurrence of tumor lysis syndrome after the infusion of 2-chlorodeoxyadenosine in a patient with CLL and bulky lymphadenopathy…

AB - The deoxyadenosine analogue 2-chlorodeoxyadenosine is an effective and relatively nontoxic treatment for hairy-cell leukemia1 and other B-cell neoplasms, including chronic lymphocytic leukemia (CLL)2,3. In a recent study of 90 patients with CLL, including 62 with advanced disease, the overall rate of response was 44 percent, the most severe toxic effect being myelosuppression4. Excellent responses were recently reported in four patients who did not respond to fludarabine therapy, with myelosuppression as the only untoward side effect5. We report the occurrence of tumor lysis syndrome after the infusion of 2-chlorodeoxyadenosine in a patient with CLL and bulky lymphadenopathy…

UR - http://www.scopus.com/inward/record.url?scp=0027527856&partnerID=8YFLogxK

U2 - 10.1056/NEJM199311183292106

DO - 10.1056/NEJM199311183292106

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

C2 - 8105383

AN - SCOPUS:0027527856

SN - 0028-4793

VL - 329

SP - 1547

EP - 1548

JO - New England Journal of Medicine

JF - New England Journal of Medicine

IS - 21

ER -

Tumor Lysis Syndrome Following Treatment with 2-Chlorodeoxyadenosine for Refractory Chronic Lymphocytic Leukemia

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this